Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning

L. J. Decook, M. Thoma, T. Huneke, N. D. Johnson, R. A. Wiegand, Mrinal M Patnaik, Mark R Litzow, William Hogan, L. F. Porrata, S. G. Holtan

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

We have recently shown that lymphocyte and monocyte recovery by day +100 are associated with survival post myeloablative allogeneic hematopoietic transplant for acute leukemia. We hypothesized that lymphocyte and monocyte recovery would have a similar impact on survival in the reduced intensity setting. To test this hypothesis, we analyzed clinical data from 118 consecutive fludarabine/melphalan-conditioned patients by correlating peripheral blood absolute lymphocyte counts and monocyte counts (ALC and AMC, respectively) at days +15, +30, +60 and +100 with the outcomes. Multivariate analysis revealed that day +100 AMC (risk ratio (RR) 0.22, 95% confidence interval (CI) 0.07-0.73, P=0.01) and mild chronic GVHD (RR 0.09, 95% CI 0.005-0.43, P=0.008) were independently associated with survival. To explore whether the patterns of lymphocyte and monocyte recovery had a prognostic value, we performed unsupervised hierarchical clustering on the studied hematopoietic parameters and identified three patient clusters, A-C. Patient clusters A and B both had improved OS compared with cluster C (77.8 months vs not reached vs 22.3 months, respectively, P<0.001). No patient in cluster C had a day +100 AMC >300. Both severe acute GVHD and relapse occurred more frequently in cluster C. Our data suggest that patients with low AMC by day +100 post fludarabine/melphalan- conditioned allogeneic hematopoietic SCT may be at risk for poor outcomes.

Original languageEnglish (US)
Pages (from-to)708-714
Number of pages7
JournalBone Marrow Transplantation
Volume48
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Melphalan
Monocytes
Lymphocytes
Survival
Odds Ratio
Confidence Intervals
Lymphocyte Count
Cluster Analysis
Leukemia
Multivariate Analysis
Transplants
Recurrence
fludarabine

Keywords

  • GVHD
  • immune reconstitution
  • lymphocyte
  • monocyte
  • reduced intensity allogeneic hematopoietic SCT
  • relapse

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning. / Decook, L. J.; Thoma, M.; Huneke, T.; Johnson, N. D.; Wiegand, R. A.; Patnaik, Mrinal M; Litzow, Mark R; Hogan, William; Porrata, L. F.; Holtan, S. G.

In: Bone Marrow Transplantation, Vol. 48, No. 5, 05.2013, p. 708-714.

Research output: Contribution to journalArticle

Decook, L. J. ; Thoma, M. ; Huneke, T. ; Johnson, N. D. ; Wiegand, R. A. ; Patnaik, Mrinal M ; Litzow, Mark R ; Hogan, William ; Porrata, L. F. ; Holtan, S. G. / Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning. In: Bone Marrow Transplantation. 2013 ; Vol. 48, No. 5. pp. 708-714.
@article{d1c2a803012e4524aa4a455e61de5c0e,
title = "Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning",
abstract = "We have recently shown that lymphocyte and monocyte recovery by day +100 are associated with survival post myeloablative allogeneic hematopoietic transplant for acute leukemia. We hypothesized that lymphocyte and monocyte recovery would have a similar impact on survival in the reduced intensity setting. To test this hypothesis, we analyzed clinical data from 118 consecutive fludarabine/melphalan-conditioned patients by correlating peripheral blood absolute lymphocyte counts and monocyte counts (ALC and AMC, respectively) at days +15, +30, +60 and +100 with the outcomes. Multivariate analysis revealed that day +100 AMC (risk ratio (RR) 0.22, 95{\%} confidence interval (CI) 0.07-0.73, P=0.01) and mild chronic GVHD (RR 0.09, 95{\%} CI 0.005-0.43, P=0.008) were independently associated with survival. To explore whether the patterns of lymphocyte and monocyte recovery had a prognostic value, we performed unsupervised hierarchical clustering on the studied hematopoietic parameters and identified three patient clusters, A-C. Patient clusters A and B both had improved OS compared with cluster C (77.8 months vs not reached vs 22.3 months, respectively, P<0.001). No patient in cluster C had a day +100 AMC >300. Both severe acute GVHD and relapse occurred more frequently in cluster C. Our data suggest that patients with low AMC by day +100 post fludarabine/melphalan- conditioned allogeneic hematopoietic SCT may be at risk for poor outcomes.",
keywords = "GVHD, immune reconstitution, lymphocyte, monocyte, reduced intensity allogeneic hematopoietic SCT, relapse",
author = "Decook, {L. J.} and M. Thoma and T. Huneke and Johnson, {N. D.} and Wiegand, {R. A.} and Patnaik, {Mrinal M} and Litzow, {Mark R} and William Hogan and Porrata, {L. F.} and Holtan, {S. G.}",
year = "2013",
month = "5",
doi = "10.1038/bmt.2012.211",
language = "English (US)",
volume = "48",
pages = "708--714",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning

AU - Decook, L. J.

AU - Thoma, M.

AU - Huneke, T.

AU - Johnson, N. D.

AU - Wiegand, R. A.

AU - Patnaik, Mrinal M

AU - Litzow, Mark R

AU - Hogan, William

AU - Porrata, L. F.

AU - Holtan, S. G.

PY - 2013/5

Y1 - 2013/5

N2 - We have recently shown that lymphocyte and monocyte recovery by day +100 are associated with survival post myeloablative allogeneic hematopoietic transplant for acute leukemia. We hypothesized that lymphocyte and monocyte recovery would have a similar impact on survival in the reduced intensity setting. To test this hypothesis, we analyzed clinical data from 118 consecutive fludarabine/melphalan-conditioned patients by correlating peripheral blood absolute lymphocyte counts and monocyte counts (ALC and AMC, respectively) at days +15, +30, +60 and +100 with the outcomes. Multivariate analysis revealed that day +100 AMC (risk ratio (RR) 0.22, 95% confidence interval (CI) 0.07-0.73, P=0.01) and mild chronic GVHD (RR 0.09, 95% CI 0.005-0.43, P=0.008) were independently associated with survival. To explore whether the patterns of lymphocyte and monocyte recovery had a prognostic value, we performed unsupervised hierarchical clustering on the studied hematopoietic parameters and identified three patient clusters, A-C. Patient clusters A and B both had improved OS compared with cluster C (77.8 months vs not reached vs 22.3 months, respectively, P<0.001). No patient in cluster C had a day +100 AMC >300. Both severe acute GVHD and relapse occurred more frequently in cluster C. Our data suggest that patients with low AMC by day +100 post fludarabine/melphalan- conditioned allogeneic hematopoietic SCT may be at risk for poor outcomes.

AB - We have recently shown that lymphocyte and monocyte recovery by day +100 are associated with survival post myeloablative allogeneic hematopoietic transplant for acute leukemia. We hypothesized that lymphocyte and monocyte recovery would have a similar impact on survival in the reduced intensity setting. To test this hypothesis, we analyzed clinical data from 118 consecutive fludarabine/melphalan-conditioned patients by correlating peripheral blood absolute lymphocyte counts and monocyte counts (ALC and AMC, respectively) at days +15, +30, +60 and +100 with the outcomes. Multivariate analysis revealed that day +100 AMC (risk ratio (RR) 0.22, 95% confidence interval (CI) 0.07-0.73, P=0.01) and mild chronic GVHD (RR 0.09, 95% CI 0.005-0.43, P=0.008) were independently associated with survival. To explore whether the patterns of lymphocyte and monocyte recovery had a prognostic value, we performed unsupervised hierarchical clustering on the studied hematopoietic parameters and identified three patient clusters, A-C. Patient clusters A and B both had improved OS compared with cluster C (77.8 months vs not reached vs 22.3 months, respectively, P<0.001). No patient in cluster C had a day +100 AMC >300. Both severe acute GVHD and relapse occurred more frequently in cluster C. Our data suggest that patients with low AMC by day +100 post fludarabine/melphalan- conditioned allogeneic hematopoietic SCT may be at risk for poor outcomes.

KW - GVHD

KW - immune reconstitution

KW - lymphocyte

KW - monocyte

KW - reduced intensity allogeneic hematopoietic SCT

KW - relapse

UR - http://www.scopus.com/inward/record.url?scp=84877645033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877645033&partnerID=8YFLogxK

U2 - 10.1038/bmt.2012.211

DO - 10.1038/bmt.2012.211

M3 - Article

C2 - 23103674

AN - SCOPUS:84877645033

VL - 48

SP - 708

EP - 714

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -